Cure My Disease

Don't miss your cure!

 Log in / Sign up

New leukemia pill aims for fewer side effects in major trial

NCT ID NCT05456191

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study compares two oral medications, asciminib and nilotinib, for adults newly diagnosed with a specific type of chronic leukemia (Ph+ CML). The main goal is to see which drug is better tolerated, meaning it causes fewer side effects that make people stop taking it. Researchers also measure how well each drug controls the leukemia in the blood over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Illinois Cancer Care

    Peoria, Illinois, 61615, United States

  • Messino Cancer Centers

    Asheville, North Carolina, 28806, United States

  • Novartis Investigative Site

    CABA, Buenos Aires, C1221ADH, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1114AAN, Argentina

  • Novartis Investigative Site

    Buenos Aires, C1425AUM, Argentina

  • Novartis Investigative Site

    Caba, C1039AAC, Argentina

  • Novartis Investigative Site

    CABA, C1181ACH, Argentina

  • Novartis Investigative Site

    Pleven, 5800, Bulgaria

  • Novartis Investigative Site

    Plovdiv, 4002, Bulgaria

  • Novartis Investigative Site

    Sofia, 1431, Bulgaria

  • Novartis Investigative Site

    Sofia, 1797, Bulgaria

  • Novartis Investigative Site

    Varna, 9010, Bulgaria

  • Novartis Investigative Site

    London, Ontario, N6A 5W9, Canada

  • Novartis Investigative Site

    Toronto, Ontario, M5G 2M9, Canada

  • Novartis Investigative Site

    Brno, 625 00, Czechia

  • Novartis Investigative Site

    Plzen Bory, 301 00, Czechia

  • Novartis Investigative Site

    Prague, 100 34, Czechia

  • Novartis Investigative Site

    Prague, 128 00, Czechia

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Caen, 14033, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63003, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Marseille, 13273, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Nice, 06202, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Strasbourg, 67000, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511, France

  • Novartis Investigative Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, 68305, Germany

  • Novartis Investigative Site

    Munich, Bavaria, 81241, Germany

  • Novartis Investigative Site

    Würzburg, Bavaria, 97080, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    Marburg, Hesse, 35043, Germany

  • Novartis Investigative Site

    Paderborn, North Rhine-Westphalia, 33098, Germany

  • Novartis Investigative Site

    Velbert, North Rhine-Westphalia, 42551, Germany

  • Novartis Investigative Site

    Dresden, Saxony, 01307, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, 04103, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, 06120, Germany

  • Novartis Investigative Site

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    Aachen, 52074, Germany

  • Novartis Investigative Site

    Augsburg, 86179, Germany

  • Novartis Investigative Site

    Bad Saarow, 15526, Germany

  • Novartis Investigative Site

    Bayreuth, 95445, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Bremen, 28205, Germany

  • Novartis Investigative Site

    Chemnitz, 09113, Germany

  • Novartis Investigative Site

    Erlangen, 91054, Germany

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Hamburg, 20246, Germany

  • Novartis Investigative Site

    Hanover, 30161, Germany

  • Novartis Investigative Site

    Heidelberg, 69120, Germany

  • Novartis Investigative Site

    Lübeck, 23538, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    München, 80377, Germany

  • Novartis Investigative Site

    Regensburg, 93049, Germany

  • Novartis Investigative Site

    Tübingen, 72076, Germany

  • Novartis Investigative Site

    Ulm, 89081, Germany

  • Novartis Investigative Site

    Athens, 106 76, Greece

  • Novartis Investigative Site

    Athens, 115 27, Greece

  • Novartis Investigative Site

    Ioannina, 455 00, Greece

  • Novartis Investigative Site

    Pátrai, 265 04, Greece

  • Novartis Investigative Site

    Thessaloniki, 570 10, Greece

  • Novartis Investigative Site

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    Budapest, H-1097, Hungary

  • Novartis Investigative Site

    Eger, 3300, Hungary

  • Novartis Investigative Site

    Ahmedabad, Gujarat, 380009, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, 110029, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600036, India

  • Novartis Investigative Site

    Varanasi, Uttar Pradesh, 221010, India

  • Novartis Investigative Site

    Rishikesh, Uttarakhand, 249203, India

  • Novartis Investigative Site

    Meldola, FC, 47014, Italy

  • Novartis Investigative Site

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    Pisa, PI, 56126, Italy

  • Novartis Investigative Site

    Roma, RM, 00144, Italy

  • Novartis Investigative Site

    Torino, TO, 10126, Italy

  • Novartis Investigative Site

    Amman, 11941, Jordan

  • Novartis Investigative Site

    Alor Star, Kedah, 05460, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, 93586, Malaysia

  • Novartis Investigative Site

    Petaling Jaya, Selangor, 46150, Malaysia

  • Novartis Investigative Site

    Kuala Lumpur, 59100, Malaysia

  • Novartis Investigative Site

    Dordrecht, South Holland, 3318 AT, Netherlands

  • Novartis Investigative Site

    Khoudh, 123, Oman

  • Novartis Investigative Site

    Cluj-Napoca, Cluj, 400015, Romania

  • Novartis Investigative Site

    Craiova, Dolj, 200136, Romania

  • Novartis Investigative Site

    Târgu Mureş, Mureș County, 540136, Romania

  • Novartis Investigative Site

    Bucharest, 021494, Romania

  • Novartis Investigative Site

    Bucharest, 022328, Romania

  • Novartis Investigative Site

    Bucharest, 030 171, Romania

  • Novartis Investigative Site

    Sibiu, 550245, Romania

  • Novartis Investigative Site

    Timișoara, 300079, Romania

  • Novartis Investigative Site

    Singapore, 119074, Singapore

  • Novartis Investigative Site

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    Singapore, S308433, Singapore

  • Novartis Investigative Site

    Bratislava, 851 07, Slovakia

  • Novartis Investigative Site

    Johannesburg, Gauteng, 2013, South Africa

  • Novartis Investigative Site

    Pretoria, Gauteng, 0181, South Africa

  • Novartis Investigative Site

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    Geneva, 1211, Switzerland

  • Novartis Investigative Site

    Istanbul, Fatih, 34098, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, 35100, Turkey (Türkiye)

  • Novartis Investigative Site

    Abu Dhabi, 00000, United Arab Emirates

  • Novartis Investigative Site

    Glasgow, G12 0YN, United Kingdom

  • Novartis Investigative Site

    Gloucester, GL1 3NN, United Kingdom

  • Novartis Investigative Site

    London, SE5 9RS, United Kingdom

  • Novartis Investigative Site

    London, W12 0HS, United Kingdom

  • Novartis Investigative Site

    Newport, NP20 2UB, United Kingdom

  • Oncology Hematology Care Inc

    Cincinnati, Ohio, 45242, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Rocky Mountain Cancer Centers

    Denver, Colorado, 80218, United States

  • Texas Oncology P A

    Bedford, Texas, 76022, United States

  • Texas Oncology PA Bedford

    Bedford, Texas, 76022, United States

  • Virginia Oncology Associates

    Norfolk, Virginia, 23502, United States

  • Williamette Cancer Center

    Eugene, Oregon, 97401, United States

Conditions

Explore the condition pages connected to this study.

PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA